{"id":"macitentan-act-064992","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Flushing"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Endothelin is a potent vasoconstrictor that plays a key role in the pathophysiology of pulmonary arterial hypertension. By antagonizing both ETA and ETB receptors on vascular smooth muscle and endothelial cells, macitentan reduces vasoconstriction, inhibits cell proliferation, and decreases inflammation in the pulmonary vasculature. This leads to improved hemodynamics and clinical outcomes in PAH patients.","oneSentence":"Macitentan is a dual endothelin receptor antagonist that blocks both ETA and ETB receptors to reduce pulmonary vascular resistance and improve exercise capacity in pulmonary arterial hypertension.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:01.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension (PAH)"}]},"trialDetails":[{"nctId":"NCT02932410","phase":"PHASE3","title":"A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Actelion","startDate":"2017-10-24","conditions":"Pulmonary Arterial Hypertension","enrollment":165},{"nctId":"NCT03904693","phase":"PHASE3","title":"Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Actelion","startDate":"2019-07-29","conditions":"Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)","enrollment":187},{"nctId":"NCT05167825","phase":"PHASE3","title":"A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2022-11-14","conditions":"Pulmonary Arterial Hypertension","enrollment":7},{"nctId":"NCT05140525","phase":"PHASE3","title":"Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH","status":"RECRUITING","sponsor":"Dr Sudarshan Rajagopal","startDate":"2025-01-27","conditions":"CTEPH","enrollment":15},{"nctId":"NCT04271475","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension","status":"TERMINATED","sponsor":"Actelion","startDate":"2020-07-07","conditions":"Chronic Thromboembolic Pulmonary Hypertension","enrollment":127},{"nctId":"NCT03215966","phase":"PHASE1","title":"A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2017-08-07","conditions":"Healthy Subjects","enrollment":38},{"nctId":"NCT03359291","phase":"PHASE1","title":"Clinical Study to Investigate the Effect of Macitentan on the Concentrations of Rosuvastatin in the Blood of Healthy Male Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2017-11-03","conditions":"Healthy Subjects","enrollment":20},{"nctId":"NCT03422328","phase":"PHASE3","title":"A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.","status":"COMPLETED","sponsor":"Actelion","startDate":"2018-04-05","conditions":"Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension","enrollment":151},{"nctId":"NCT02112487","phase":"PHASE3","title":"Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH","status":"COMPLETED","sponsor":"Actelion","startDate":"2014-06-23","conditions":"Pulmonary Arterial Hypertension","enrollment":88},{"nctId":"NCT04963439","phase":"PHASE1","title":"A Study of Two Macitentan Pediatric Formulations in Healthy Adult Participants","status":"COMPLETED","sponsor":"Actelion","startDate":"2021-07-08","conditions":"Healthy","enrollment":16},{"nctId":"NCT05433675","phase":"PHASE1","title":"A Study of Two Macitentan Formulations in Healthy Adult Participants","status":"COMPLETED","sponsor":"Actelion","startDate":"2022-06-22","conditions":"Healthy","enrollment":28},{"nctId":"NCT05392530","phase":"PHASE1","title":"A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult Participants","status":"COMPLETED","sponsor":"Actelion","startDate":"2022-05-25","conditions":"Healthy","enrollment":23},{"nctId":"NCT04235270","phase":"PHASE1","title":"A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-01-17","conditions":"Healthy","enrollment":62},{"nctId":"NCT00667823","phase":"PHASE3","title":"Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2008-10-17","conditions":"Pulmonary Arterial Hypertension","enrollment":550},{"nctId":"NCT02126943","phase":"","title":"OPsumit USers Registry","status":"COMPLETED","sponsor":"Actelion","startDate":"2014-04-30","conditions":"Pulmonary Arterial Hypertension","enrollment":2686},{"nctId":"NCT03197688","phase":"","title":"Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States","status":"COMPLETED","sponsor":"Actelion","startDate":"2017-08-03","conditions":"Pulmonary Arterial Hypertension","enrollment":2200},{"nctId":"NCT02021292","phase":"PHASE2","title":"Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2014-08-20","conditions":"Chronic Thromboembolic Pulmonary Hypertension","enrollment":80},{"nctId":"NCT02060721","phase":"PHASE2","title":"Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2015-02-03","conditions":"Chronic Thromboembolic Pulmonary Hypertension","enrollment":76},{"nctId":"NCT04540744","phase":"PHASE1","title":"A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-30","conditions":"Healthy","enrollment":18},{"nctId":"NCT02382016","phase":"PHASE4","title":"PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial","status":"COMPLETED","sponsor":"Actelion","startDate":"2015-06-23","conditions":"Portopulmonary Hypertension","enrollment":85},{"nctId":"NCT02310672","phase":"PHASE4","title":"REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension","status":"COMPLETED","sponsor":"Actelion","startDate":"2015-06-01","conditions":"Pulmonary Arterial Hypertension","enrollment":89},{"nctId":"NCT05236231","phase":"PHASE1","title":"A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants","status":"COMPLETED","sponsor":"Actelion","startDate":"2022-02-04","conditions":"Healthy","enrollment":40},{"nctId":"NCT03153111","phase":"PHASE2","title":"A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease","status":"COMPLETED","sponsor":"Actelion","startDate":"2017-07-11","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":143},{"nctId":"NCT03726398","phase":"PHASE2, PHASE3","title":"CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH","status":"WITHDRAWN","sponsor":"Franz Rischard, DO","startDate":"2018-09-01","conditions":"Interstitial Lung Disease, Scleroderma, Pulmonary Hypertension","enrollment":""},{"nctId":"NCT01474122","phase":"PHASE3","title":"Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients","status":"TERMINATED","sponsor":"Actelion","startDate":"2011-12","conditions":"Digital Ulcers","enrollment":265},{"nctId":"NCT02050802","phase":"PHASE1","title":"Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-08","conditions":"Healthy","enrollment":64},{"nctId":"NCT02476864","phase":"PHASE1","title":"Comparison of the Pharmacokinetic Properties of Two Tablet Formulations of Macitentan in Healthy Adults","status":"COMPLETED","sponsor":"Actelion","startDate":"2015-08","conditions":"Healthy Subjects","enrollment":12},{"nctId":"NCT05373108","phase":"PHASE4","title":"Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-05-19","conditions":"Cardiac Allograft Vasculopathy","enrollment":19},{"nctId":"NCT03809650","phase":"PHASE3","title":"A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).","status":"TERMINATED","sponsor":"Actelion","startDate":"2019-01-08","conditions":"Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","enrollment":9},{"nctId":"NCT02893176","phase":"PHASE4","title":"Macitentan in the Treatment of Organ Rejection After Lung Transplantation","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2016-09","conditions":"Lung Transplant Rejection","enrollment":""},{"nctId":"NCT02651272","phase":"PHASE2","title":"Macitentan in Pulmonary Hypertension of Sickle Cell Disease","status":"TERMINATED","sponsor":"Boston University","startDate":"2015-07","conditions":"Pulmonary Hypertension, Sickle Cell Disease","enrollment":4},{"nctId":"NCT02070991","phase":"PHASE2","title":"Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction","status":"COMPLETED","sponsor":"Actelion","startDate":"2014-07-01","conditions":"Pulmonary Hypertension","enrollment":63},{"nctId":"NCT01739400","phase":"PHASE3","title":"Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome","status":"TERMINATED","sponsor":"Actelion","startDate":"2013-09-10","conditions":"Pulmonary Arterial Hypertension","enrollment":217},{"nctId":"NCT02885012","phase":"PHASE4","title":"Crossover Study From Macitentan or Bosentan Over to Ambrisentan","status":"TERMINATED","sponsor":"Medical University of South Carolina","startDate":"2016-06","conditions":"Pulmonary Arterial Hypertension","enrollment":3},{"nctId":"NCT01841762","phase":"PHASE3","title":"Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument","status":"COMPLETED","sponsor":"Actelion","startDate":"2013-04-01","conditions":"Pulmonary Arterial Hypertension","enrollment":284},{"nctId":"NCT01847014","phase":"PHASE3","title":"Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument","status":"TERMINATED","sponsor":"Actelion","startDate":"2013-09-01","conditions":"Pulmonary Arterial Hypertension","enrollment":4},{"nctId":"NCT01389206","phase":"","title":"Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-06-01","conditions":"Pulmonary Arterial Hypertension","enrollment":797},{"nctId":"NCT01743001","phase":"PHASE3","title":"Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome","status":"COMPLETED","sponsor":"Actelion","startDate":"2013-05-21","conditions":"Pulmonary Arterial Hypertension","enrollment":226},{"nctId":"NCT03389321","phase":"PHASE1","title":"Clinical Study to Investigate Effect of Macitentan on Riociguat Pharmacokinetics","status":"COMPLETED","sponsor":"Actelion","startDate":"2018-01-09","conditions":"Healthy Subjects","enrollment":20},{"nctId":"NCT01266265","phase":"","title":"Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2010-12","conditions":"Pulmonary Arterial Hypertension","enrollment":1333},{"nctId":"NCT00660179","phase":"PHASE3","title":"Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2008-05","conditions":"Pulmonary Arterial Hypertension","enrollment":742},{"nctId":"NCT01474109","phase":"PHASE3","title":"Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-12","conditions":"Systemic Sclerosis, Ulcers","enrollment":289},{"nctId":"NCT00903331","phase":"PHASE2","title":"Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study","status":"COMPLETED","sponsor":"Actelion","startDate":"2009-05","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":178}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"macitentan (ACT-064992)","genericName":"macitentan (ACT-064992)","companyName":"Actelion","companyId":"actelion","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Macitentan is a dual endothelin receptor antagonist that blocks both ETA and ETB receptors to reduce pulmonary vascular resistance and improve exercise capacity in pulmonary arterial hypertension. Used for Pulmonary arterial hypertension (PAH).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}